Katharina Leonards
Overview
Explore the profile of Katharina Leonards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
257
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adam F, Szybinski J, Halter J, Cantoni N, Wenzel F, Leonards K, et al.
Curr Oncol
. 2022 Feb;
29(2):805-815.
PMID: 35200567
Chronic neutrophilic leukemia (CNL) relates to mutational CSF3R activation with membrane proximal mutations such as T618I as driver mutations, but the significance of truncating mutations is not clarified. In CNL,...
2.
Brkic S, Stivala S, Santopolo A, Szybinski J, Jungius S, Passweg J, et al.
Leukemia
. 2021 Sep;
35(10):2875-2884.
PMID: 34480104
Myeloproliferative neoplasms (MPN) show dysregulated JAK2 signaling. JAK2 inhibitors provide clinical benefits, but compensatory activation of MAPK pathway signaling impedes efficacy. We hypothesized that dual targeting of JAK2 and ERK1/2...
3.
Fenizia F, Alborelli I, Costa J, Vollbrecht C, Bellosillo B, Dinjens W, et al.
J Mol Diagn
. 2021 May;
23(7):882-893.
PMID: 33964449
Tumor mutation burden (TMB) is evaluated as a biomarker of response to immunotherapy. We present the efforts of the Onconetwork Immuno-Oncology Consortium to validate a commercial targeted sequencing test for...
4.
Alborelli I, Hench I, Chijioke O, Savic Prince S, Bubendorf L, Leuenberger L, et al.
Lung Cancer
. 2020 Sep;
149:84-89.
PMID: 32980613
Objectives: Tumor mutational burden (TMB) has emerged as a promising predictive biomarker for immune checkpoint inhibitor therapy. While the feasibility of TMB analysis on formalin-fixed paraffin-embedded (FFPE) samples has been...
5.
Leonards K, Almosailleakh M, Tauchmann S, Bagger F, Thirant C, Juge S, et al.
Nat Commun
. 2020 Jun;
11(1):2807.
PMID: 32533074
The nuclear receptor binding SET domain protein 1 (NSD1) is recurrently mutated in human cancers including acute leukemia. We show that NSD1 knockdown alters erythroid clonogenic growth of human CD34...
6.
Alborelli I, Leonards K, Rothschild S, Leuenberger L, Savic Prince S, Mertz K, et al.
J Pathol
. 2019 Sep;
250(1):19-29.
PMID: 31471895
In non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) significantly improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive biomarker for patients treated with ICIs....
7.
Picaud S, Leonards K, Lambert J, Dovey O, Wells C, Fedorov O, et al.
Sci Adv
. 2016 Oct;
2(10):e1600760.
PMID: 27757418
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy. The development of selective and potent BET (bromo and extra-terminal) inhibitors and their significant activity in diverse tumor models have...
8.
Picaud S, Fedorov O, Thanasopoulou A, Leonards K, Jones K, Meier J, et al.
Cancer Res
. 2015 Nov;
75(23):5106-5119.
PMID: 26552700
The histone acetyltransferases CBP/p300 are involved in recurrent leukemia-associated chromosomal translocations and are key regulators of cell growth. Therefore, efforts to generate inhibitors of CBP/p300 are of clinical value. We...